Araştırma
Eğitim
Çözümler
Oturum Aç
TR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Department of Molecular Oncology,
Cancer Research Institute,
Department of Molecular Oncology, Cancer Research Institute
Verona Buocikova has not added Biography.
If you are Verona Buocikova and would like to personalize this page please email our Author Liaison for assistance.
Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives.
Cancers Dec, 2020 | Pubmed ID: 33287297
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Mar, 2022 | Pubmed ID: 35091237
Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression.
Frontiers in pharmacology , 2022 | Pubmed ID: 36278182
Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms.
Critical reviews in oncology/hematology Dec, 2022 | Pubmed ID: 36334880
Genotoxic effects of occupational exposure to glass fibres - A human biomonitoring study.
Mutation research. Genetic toxicology and environmental mutagenesis Jan, 2023 | Pubmed ID: 36669817
Biomedical Research Center of the Slovak Academy of Sciences
Jesús Frutos Díaz-Alejo*,1,2,3,4,
Simon April-Monn*,5,
Marina Cihova6,
Verona Buocikova6,
Jorge Villalón López1,3,
Maria Urbanova6,
Carmen G. Lechuga7,
Miroslav Tomas6,8,
Peter Dubovan6,8,
Bárbara Luna Sánchez3,
Sonia Camaño Páez3,
Alfonso Sanjuanbenito2,9,
Eduardo Lobo9,
Estefanía Romio de la Heras10,
Carmen Guerra2,7,
Carolina de la Pinta11,
Emma Barreto Melian1,2,
Mercedes Rodríguez Garrote1,2,
Alfredo Carrato1,2,4,
Laura Ruiz-Cañas3,12,13,
Bruno Sainz, Jr.2,3,12,13,
Ana Torres3,
Bozena Smolkova6,
Julie Earl1,2,3
1Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS),
2, The Biomedical Research Network in Cancer (CIBERONC),
3Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS),
4Faculty of Medicine, University of Alcalá de Henares,
5Institute of Tissue Medicine and Pathology, University of Bern,
6Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences,
7Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO),
8Department of Surgical Oncology, National Cancer Institute, Slovak Medical University,
9Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal,
10Department of Pathology, Hospital Universitario Ramón y Cajal,
11Department of Radiation Oncology, Hospital Universitario Ramón y Cajal,
12Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM),
13Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS
Gizlilik
Kullanım Şartları
İlkeler
Bize Ulaşın
KÜTÜPHANEYE TAVSİYE ET
JoVE HABER BÜLTENLERİ
JoVE Journal
Yöntem Koleksiyonları
JoVE Encyclopedia of Experiments
Arşiv
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Fakülte Kaynak Merkezi
Yazarlar
Kütüphaneciler
Erişim
JoVE Hakkında
Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır